Abstract
Abstract Introduction Glioblastoma (GBM) is the most common primary adult brain tumour with 12–15 months median overall survival. Molecular characterization of multiple immuno-onology targets in GBM is required to optimise immunotherapeutic strategies. Advanced molecular characterisation using Digital Spatial Profiling Technology allows assessment of multiple immuno-oncology protein targets in methylated compared with unmethylated Glioblastoma IDH-wildtype. Methods Nanostring DSP uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue Regions of interest (ROI) are selected with bound fluorescent antibodies, oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immuno-oncology proteins and controls (PD-1, PD-L1, B7-H3, VISTA, CD45, CD45RO, CD3, MS4A1 (CD20), CD4, CD8A, CD68, STAT3, STAT3 (Phopshory705), GZMB, Beta-2-microglobulin, CD56, Beta-catenin, FOXP3, CD14, CD19, AKT, P-AKT, PTEN, Bcl-2, CD44, Histone H3, S6, IgG Rabbit Control, Mouse IgG Control, Pan-Cytokeratin, Ki67) from ROIs in a cohort of 10 Glioblastomas IDH-wildtype (5 methylated, 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using a linear mixed effect model for technical and biological replicates. Results GeoMx DSP showed 10/27 immuno-oncology target proteins were significantly increased in methylated versus unmethylated Glioblastoma IDH-wildtype (false discovery rate FDR <0.1 by Benjamini-Hocheberg Procedure). Conclusions Increased immuno-oncology protein target expression in methylated versus unmethylated glioblastoma IDH-wildtype using DSP platform has been identified. Advanced multiplex immuno-oncological biomarker analysis is required to identify predictive biomarkers for novel immunotherapeutic agents in GBMs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
